Myeloproliferative neoplasms 2012: The John M. Bennett 80th birthday anniversary lecture

Ayalew Tefferi

doi:10.1016/j.leukres.2012.08.011

Myeloproliferative neoplasms 2012: The John M. Bennett 80th birthday anniversary lecture

Ayalew Tefferi

Hematology

Research output: Contribution to journal › Review article › peer-review

11 Scopus citations

Abstract

Polycythemia vera, essential thrombocythemia and primary myelofibrosis constitute the BCR-ABL1-negative myeloproliferative neoplasms. In this communication, I will provide an overview on their histopathology, cytogenetic findings and associated mutations, as well as summarize recent advances that have changed our approach to their diagnosis and treatment. Also included in the current review are (i) indications for ordering JAK2 or MPL mutation analysis and result interpretation, (ii) new international prognostic scoring systems, and (iii) risk-adapted therapy including the therapeutic role of immunomodulatory drugs and JAK inhibitors.

Original language	English (US)
Pages (from-to)	1481-1489
Number of pages	9
Journal	Leukemia Research
Volume	36
Issue number	12
DOIs	https://doi.org/10.1016/j.leukres.2012.08.011
State	Published - Dec 1 2012

Keywords

Myelodysplastic syndromes (MDS)
Myeloproliferative neoplasms (MPN)

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1016/j.leukres.2012.08.011

Cite this

@article{739870c0efd74846884cef3ab657a9ca,

title = "Myeloproliferative neoplasms 2012: The John M. Bennett 80th birthday anniversary lecture",

abstract = "Polycythemia vera, essential thrombocythemia and primary myelofibrosis constitute the BCR-ABL1-negative myeloproliferative neoplasms. In this communication, I will provide an overview on their histopathology, cytogenetic findings and associated mutations, as well as summarize recent advances that have changed our approach to their diagnosis and treatment. Also included in the current review are (i) indications for ordering JAK2 or MPL mutation analysis and result interpretation, (ii) new international prognostic scoring systems, and (iii) risk-adapted therapy including the therapeutic role of immunomodulatory drugs and JAK inhibitors.",

keywords = "Myelodysplastic syndromes (MDS), Myeloproliferative neoplasms (MPN)",

author = "Ayalew Tefferi",

year = "2012",

month = dec,

day = "1",

doi = "10.1016/j.leukres.2012.08.011",

language = "English (US)",

volume = "36",

pages = "1481--1489",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Limited",

number = "12",

}

TY - JOUR

T1 - Myeloproliferative neoplasms 2012

T2 - The John M. Bennett 80th birthday anniversary lecture

AU - Tefferi, Ayalew

PY - 2012/12/1

Y1 - 2012/12/1

N2 - Polycythemia vera, essential thrombocythemia and primary myelofibrosis constitute the BCR-ABL1-negative myeloproliferative neoplasms. In this communication, I will provide an overview on their histopathology, cytogenetic findings and associated mutations, as well as summarize recent advances that have changed our approach to their diagnosis and treatment. Also included in the current review are (i) indications for ordering JAK2 or MPL mutation analysis and result interpretation, (ii) new international prognostic scoring systems, and (iii) risk-adapted therapy including the therapeutic role of immunomodulatory drugs and JAK inhibitors.

AB - Polycythemia vera, essential thrombocythemia and primary myelofibrosis constitute the BCR-ABL1-negative myeloproliferative neoplasms. In this communication, I will provide an overview on their histopathology, cytogenetic findings and associated mutations, as well as summarize recent advances that have changed our approach to their diagnosis and treatment. Also included in the current review are (i) indications for ordering JAK2 or MPL mutation analysis and result interpretation, (ii) new international prognostic scoring systems, and (iii) risk-adapted therapy including the therapeutic role of immunomodulatory drugs and JAK inhibitors.

KW - Myelodysplastic syndromes (MDS)

KW - Myeloproliferative neoplasms (MPN)

UR - http://www.scopus.com/inward/record.url?scp=84868193850&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868193850&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2012.08.011

DO - 10.1016/j.leukres.2012.08.011

M3 - Review article

C2 - 22917768

AN - SCOPUS:84868193850

SN - 0145-2126

VL - 36

SP - 1481

EP - 1489

JO - Leukemia Research

JF - Leukemia Research

IS - 12

ER -

Myeloproliferative neoplasms 2012: The John M. Bennett 80th birthday anniversary lecture

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this